Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04062669 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
A Phase 1 study of Virus Diseases, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 4
- Study locations
NCT04062669 is a Phase 1 study of Virus Diseases that has completed, run by GlaxoSmithKline. The registered enrollment target is 160 participants, below the 1,502-participant average among 7 other Virus Diseases trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04062669, a Phase 1 study of Virus Diseases, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM \[CNE\] vaccine), made using a new technology, when administered intramuscularly (IM) on a 0, 2, 6 \*-month schedule to healthy adults. \* There will be no vaccinations with the third dose of any of the study treatments.
Conditions Studied
Interventions
- DRUG Saline Placebo
- BIOLOGICAL Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- BIOLOGICAL Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- BIOLOGICAL Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- BIOLOGICAL Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
Study Locations (4)
Florida
- GSK Investigational Site - South Miami
Kansas
- GSK Investigational Site - Lenexa
Maryland
- GSK Investigational Site - Baltimore
New York
- GSK Investigational Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04062669
The ClinicalTrials.gov registry entry for NCT04062669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,502-participant average among 7 other Virus Diseases trials with a reported enrollment target (89% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Virus Diseases appearing as the primary indexed condition, and to 5 interventions - of which Saline Placebo is the first listed.
NCT04062669 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Kansas, Maryland.
Frequently Asked Questions
What is clinical trial NCT04062669 about?
NCT04062669 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults". The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM \[CNE\] vaccine), made using a new technology, when administered intramuscularly (IM) on a 0, 2, 6 ...
What is the current status of trial NCT04062669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2019-08-13. Estimated completion is 2022-07-01.
What conditions does trial NCT04062669 study?
This clinical trial studies the following conditions: Virus Diseases.
What interventions are being tested in trial NCT04062669?
The interventions under investigation include: Saline Placebo (DRUG), Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A) (BIOLOGICAL), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A) (BIOLOGICAL), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A) (BIOLOGICAL), Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04062669?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04062669 being conducted?
This trial has 4 study locations across Florida, Kansas, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Virus Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)
COMPLETED · Phase 1
-
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
COMPLETED · Phase 1
-
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
COMPLETED · Phase 1
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluating the Human Immune Response to the JYNNEOS Vaccine
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.